GLPwatch
Papers (9189)
Page 120 of 154, ranked by citation count.
- Improved Clinical Outcomes with the Combination Therapy of a Glucagon-like Peptide-1 Receptor Agonists and a Sodium-glucose Cotransporter-2 Inhibitor in Overweight/Obese People with Type 2 Diabetes: Real-world Evidence from the Indian Subcontinent.
- Safety and effectiveness of tirzepatide during Ramadan fasting: Real-world evidence from patients with type 2 diabetes in Bangladesh.
- Recognizing overweight and obesity as chronic diseases and acknowledging root causes.
- Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database.
- Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.
- Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants.
- Tirzepatide increased force of contraction in the isolated human atrium.
- Semaglutide exposures reported to the NSW Poisons Information Centre: effects of social media marketing and supply chain disruptions.
- Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study.
- Liraglutide and Liver Injury: Rare Case Report with Literature Review.
- Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide.
- Effect of Exenatide Therapy on Platelet Function in Type 2 Diabetes Mellitus.
- In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.
- Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide.
- T2DM treatment trial results.
- Reduced incretin receptor trafficking upon activation enhances glycemic control and reverses obesity in diet-induced obese mice.
- Design of Auto-Adaptive Drug Delivery System for Effective Delivery of Peptide Drugs to Overcoming Mucus and Epithelial Barriers.
- Impact of the injectable weight-loss medications, glucagon-like peptide-1 receptor agonists, on reproductive health in non-polycystic ovary syndrome state.
- AI-Driven De Novo Design of Ultra Long-Acting GLP-1 Receptor Agonists.
- Early resuscitation with exendin-4 alleviates acute lung injury after hemorrhagic shock in rats.
- Unveiling the Therapeutic Potential of Dulaglutide in Mitigating Tacrolimus-Induced Nephrotoxicity Through Targeting the miR-22/HMGB-1/TLR4/MyD88/NF-κB Trajectory.
- Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials With Time-to-Event Outcomes Under ICH E9 (R1).
- Delayed Type Hypersensitivity Reaction Induced By Liraglutide With Tolerance to Semaglutide.
- Exendin-4 induced retching-like behavior mediated by postsynaptic effect via AMPA receptors in the area postrema of mice.
- The role of mast cells in cellular modifications evoked by Exendin-4 in treated wounds: a preclinical study.
- Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.
- Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal-bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study.
- A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.
- Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats.
- Potential roles for eNOS and NrF₂ /HO-1 signaling in the ameliorative effect of lixisenatide on diabetes-induced kidney injury in rats and its amplification by ticagrelor co-administration.
- Exendin-4, a glucagon-like peptide receptor agonist, facilitates osteoblast differentiation via connexin43.
- Increased cholesterol interactions in the active conformational state of the glucagon-like peptide-1 receptor.
- [Protective effect of glucagon-like peptide-1 analogue on cardiomyocytes injury induced by hypoxia/reoxygenation].
- Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
- Exendin-4 prevented pancreatic beta cells from apoptosis in (Type I) diabetic mouse via keap1-Nrf2 signaling.
- Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.
- Exendin-4 Exacerbates Burn-Induced Mortality in Mice by Switching to Th2 Response.
- Synthetic protease-activated class B GPCRs.
- To Assess Liraglutide's Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System.
- Acute Kidney and Liver Injury Associated With Low-Dose Liraglutide in an Obese Adolescent Patient.
- [Lixisenatide (Lyxumia), a new agonist of glucagon-like peptide-1 receptors with a predominant postprandial action].
- Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise.
- Self-Emulsifying delivery systems for oral administration of exenatide: Hydrophobic ion pairs vs. Dry reverse micelles.
- What the SELECT trial of semaglutide means for clinicians.
- Semaglutide: UK regulator approves drug for prevention of cardiovascular events.
- [Study of the effect of liraglutide on the correlation between NLRP3 inflammasome and non-alcoholic fatty liver disease].
- Hedgehog interacting protein as a circulating biomarker in women with obesity: a cross-sectional study and intervention studies.
- Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
- Ozempic keeps wowing: trial data show benefits for kidney disease.
- Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study.
- Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study.
- The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.
- In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.
- GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions.
- The Impact of Liraglutide on Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
- Semaglutide may provide sustained weight loss for at least four years, study reports.
- Daily Glucose Profiles after Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus.
- Oral semaglutide: an OASIS from injectables.
- Tirzepatide: A New Anti-Obesity Medication.
- Liraglutide Impacts Iron Homeostasis in a Murine Model of Hereditary Hemochromatosis.